HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HB-0025’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HB-0025 overview
HB-0025 is under development as a second line of therapy for the treatment of advanced solid tumors, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, endometrial cancer, hepatocellular carcinoma, colorectal cancer and metastatic renal cell carcinoma. It is administered through intravenous and intravenous drip route. It is a bi-specific fusion protein. The drug candidate is a recombinant humanized anti-PD-L1 monoclonal antibody-VEGFR1 fusion protein.
Huabo Biopharm (Shanghai) overview
Huabo Biopharm (Shanghai) (Huabobio), a subsidiary of Shanghai Huaota Biopharmaceutical Co Ltd, is a pharmaceutical company that develops and markets therapies for the treatment of cancer. The company develops drugs by using a bi-functional protein technology platform, domain protein technology, and antibody engineering technology. Its pipeline products include HOT-1010 metastatic colorectal cancer advanced metastatic or recurrent NSCLC, HB002.1T, HOT-1030, HB0030, HB0025, HB0028, HB0036, HB0045, HB0052, solid tumor, autoimmune diseases, HB1734 systemic sclerosis or idiopathic pulmonary fibrosis, HOT-3010 rheumatoid arthritis, ankylosing spondylitis, and adult moderate to severe plaque psoriasis, HB0017 moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, HB0034 pustular psoriasis, systemic lupus erythematosus and ulcerative colitis, ophthalmic eye diseases HB002.1M Huabobio’s antibody engineering technology and bi-functional protein technology platform support in development of protein and antibody drugs with improved therapeutic efficacy. Huabobio is headquartered in Shanghai, China.
For a complete picture of HB-0025’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
